Your mission The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
It was created in 2010, and since then has experienced an exponential growth.
The IJC is also part of the network of Excellence Research Centers of Catalonia ( CERCA ) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024.
Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer ( FCAECC ) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII) .
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services.
The IJC has six locations integrated into reference hospitals : Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar and Hospital San Joan de Déu.
This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.
RESEARCH DESCRIPTION The Cuartero lab is seeking a highly motivated RESEARCHER ASSISTANT to join our team.
We investigate the mechanisms that regulate transcription in normal blood development and leukemia.
Acute myeloid leukemia (AML) is one of the most aggressive forms of leukemia, and there is an urgent need for new treatment options.
Although the genes recurrently mutated in AML are known, the reasons these mutations drive malignancy remain unclear.
Our research aims to address the following questions: 1.
What transcriptional mechanisms are deregulated in acute myeloid leukemia?
2.
How do inflammatory signals influence leukemic progression?
3.
Can inflammatory modulation attenuate the severity of myeloid malignancies?
Our previous work has demonstrated that alterations in enhancer-promoter contacts and three-dimensional genome organization are critical drivers of leukemia.
We are now focused on identifying additional proteins involved in these processes.
We encourage applications from highly motivated scientists with a strong interest in epigenetics, hematopoiesis, or leukemia.
This contract is part of the RYC2021-033018-I grant funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGeneration EU/PRTR.
Your profile WHAT WE NEED We are seeking a highly motivated, talented researcher assistant to join our team and contribute to this exciting project.
General skills A committed scientist with a competitive scientific record and experience in biology, biomedicine, or related disciplines.
A high level of motivation and interest in biomedical research.
Good communication skills.
Fluent in English Technical skills Degree in Biology, Biomedicine or related field.
MSc in Biomedicine, Genetics, Immunology or related field.
Why us?
WHAT WE OFFER Temporary contract (11 months) Incorporation in a multinational and highly collaborative team.
An innovative and interdisciplinary research project.
Mixed basic and clinical research environment of the Josep Carreras Leukaemia Research Institute.
The stimulating environment of the Barcelona metropolitan area.
This contract is part of the RYC2021-033018-I grant funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGeneration EU/PRTR.
Deadline DEADLINE FOR APPLICATIONS Please submit your application by 03/01/2025 About us What makes us different?
The mission of the Josep Carreras Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer, with a special emphasis on leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
The IJC's vision is to be a world-class reference and excellent research multicampus that contributes to the improvement of results, and the cure of patients affected by leukemia and other malignant hemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.
HR Excellence In 2019, IJC was honored with the "Human Resources Excellence in Research Award" by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers.
The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC's commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The IJC is an equal opportunity employer.
We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.